
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV's focus on developing gene therapies for severe genetic conditions, particularly in hemophilia, Huntington's disease, and cardiovascular diseases, positions the company favorably within the biopharmaceutical sector. The recent encouraging data from Phase 1/2 studies of AMT-130 demonstrated exceptional efficacy and a strong biomarker profile, reinforcing its potential despite recent regulatory challenges, which management believes stem from process rather than data concerns. Furthermore, positive feedback from the FDA regarding the accelerated approval pathway and the lack of new safety or manufacturing issues strengthens uniQure's long-term outlook and enhances investor confidence in its innovative gene therapy pipeline.
Bears say
The negative outlook on uniQure NV's stock is primarily influenced by the likelihood of significant delays in the Biologics License Application (BLA) process for its candidate AMT-130, following the withdrawal of management's previous guidance for a submission in 1Q26. Additionally, the absence of any revenue-generating products, coupled with ongoing financial losses since the firm's inception, exacerbates concerns regarding its fiscal stability and operational viability. Lastly, increasing market competition from existing therapies presents a substantial risk to uniQure's potential market penetration and pricing strategy, further complicating its path to profitability.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares